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Two risk factors for the development and progression of cancers that are amenable to life style modification are
chronic inflammation and the metabolic syndrome. This review proposes two new targets that may mechanistically
integrate inflammation and metabolic syndrome, have been largely ignored, and are known to be druggable.
Recent evidence has demonstrated that elevated serum uric acid (hyperuricemia) is associated with excess cancer
risk, recurrence, and mortality. Although uric acid (UA) can function as a systemic antioxidant, its pro-inflammatory
properties have been postulated to play an important role in the pathogenesis of cancer. Furthermore, obesity,
Type 2 Diabetes Mellitus (T2DM), and the metabolic syndrome (MetS) are also associated with excess cancer,
chronic inflammation, and with hyperuricemia, suggesting that UA may represent an important link between these
disorders and the development of cancer. While pharmacological modulation of hyperuricemia could in principal
augment anti-cancer therapeutic strategies, some cancer cells express low intracellular levels of the enzyme
Xanthine Oxidoreductase (XOR) that are associated with increased cancer aggressiveness and poor clinical outcome.
Thus, systemic pharmacological inhibition of XOR may worsen clinical outcome, and specific strategies that target
serum uric acid (SUA) without inhibiting tumor cell XOR may create new therapeutic opportunities for cancer
associated with hyperuricemia. This review will summarize the evidence that elevated SUA may be a true risk factor
for cancer incidence and mortality, and mechanisms by which UA may contribute to cancer pathogenesis will be
discussed in the hope that these will identify new opportunities for cancer management.
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Hyperuricemia and cancer
UA is derived exclusively from the oxidation of xanthine
and hypoxanthine by XOR [1], and pharmacological in-
hibition of XOR has been used extensively for the man-
agement of hyperuricemic disorders such as gout,
nephrolithiasis, some cases of acute and chronic kidney
disease, ischemia-reperfusion disorders, and others [2,3].
In 1982 UA was hypothesized by Ames et al. to provide
a primary defense against human cancer based upon its
capacity to scavenge singlet oxygen, its capacity to in-
hibit lipid peroxidation, and its high serum concentra-
tion in humans [4]. Extensive support for the
physiological antioxidant function of UA was generated* Correspondence: richard.m.wright@ucdenver.edu
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pothesis, and the protective antioxidant properties of
UA have been identified in many different organ systems
[5]. Nonetheless, elevated serum urate, the dominant
monosodium form of UA at physiological pH, was found
to exhibit strong statistical association with increased
premature cancer death in both men and women [6-8]
suggesting a more complex role for UA in cancer biol-
ogy than that of a general antioxidant (Table 1).
In humans, normal SUA levels are commonly between
178 and 360 μM, (3 and 6.8 mg/dl) with higher levels
found in males and postmenopausal females than in pre-
menopausal females. Frank hyperuricemia (SUA levels >
360 μM) can reach levels of 700 μM or higher and are
associated with increasing risk for gout and acute kidney
injury arising from the deposition of monosodium urate
(MSU) crystals in the renal tubules and interstitium
[9]. Mechanisms inducing MSU crystal formation and
deposition are complex and not simply an automaticpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 References demonstrating the specific association of SUA with cancer risk, recurrence, and mortality
Reference Risk category Gender Cancer type SUA measurement
Petersson et al., 1983 Unselected M All Concurrent
Petersson et al., 1984 Unselected M All Concurrent
Levine et al., 1989 Unselected F All Prospective
Kolonel et al., 1994 Unselected M Prostate Prospective
Korenga et al., 2005 ABCG2 M/F Renal Prospective
Tsimberidou et al., 2005 MetS/Obesity M/F All Prospective
Shin et al., 2006 Unselected M/F All Concurrent
Giovannucci, 2007 MetS M/F Colon Prospective
Hu et al., 2007 ABCG2 M/F B-Cell Lymphoma Prospective
Rose et al., 2007 MetS F Breast Concurrent
Strasak et al., 2007a Unselected F All Prospective
Strasak et al., 2007b Unselected M All Prospective
Boffetta et al., 2009 Gout M/F All Prospective
Becker et al., 2009 Obesity M/F All Concurrent
Strasak et al., 2009 Unselected M/F All Prospective
Bjorge et al., 2011 MetS F Breast Concurrent
Hammarsten et al., 2011 MetS M Prostate Prospective
Panero, et al., 2011 T2DM M/F All Prospective
Siddiqui, 2011 MetS M/F Colorectal Prospective
Wang, et al., 2011 ABCG2 M/F Leukemia Prospective
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has been increasing interest that high to high normal
levels of SUA (310–330 μM), below those associated
with MSU crystal deposition, may have contributory
roles in acute renal injury [11], chronic kidney disease
[12,13], hypertension [14], cardiovascular disease (CVD)
[15-17], and MetS [18-20]. While hyperuricemia is
increased by age, menopause, alcohol consumption, and
other dietary factors, as a component of MetS, hyperuri-
cemia is associated with increased risk of colorectal,
breast, prostate, and other cancers [21-25].
Although early reports established an epidemiological
association between SUA and age, sex, and increased
death due to cancer of all types [6,7], numerous con-
founding factors including diet, alcohol consumption,
and underlying co-morbidity disorders like diabetes,
CVD, or MetS may have been responsible for the
observed association. Furthermore, cancer itself could
promote hyperuricemia through cancer related cell
death rather than being an independent risk factor for
the development of cancer. It is important to recognize
in passing that both of these early reports and subse-
quent studies that observed an association between SUA
and death due to cancer also observed an inverse rela-
tion with serum cholesterol [6,7,26]. While these publi-
cations did not explain the inverse association with
cholesterol, it is possible that the cachexia of cancer,which is associated with reduced fat stores and muscle
wasting, releases glutamate and glutamine that can in-
crease SUA levels, and indeed elevated SUA has been
associated with sarcopenia [27]. On the other hand,
in vitro analysis of liver tissue slices demonstrated that
UA itself inhibited cholesterol biosynthesis upstream of
mevalonic acid, possibly by inhibition of hydroxymethyl-
glutaryl CoA reductase [28], suggesting a potentially
broad effect of UA on cholesterol level.
Data from prospective studies, however, do suggest
that SUA may predict the development of cancer. After
adjusting for a large number of confounding factors,
Levine et al. [8] observed that SUA measured prospect-
ively at baseline before the development of cancer was
significantly associated with all site cancer mortality over
11.5 years of follow-up in women aged 55–64, and was,
therefore, unlikely to reflect hyperuricemia developed
secondarily to the development of cancer. A similar pro-
spective analysis in Japanese men used the Cox Propor-
tional Hazard Ratio (HR) to identify an association of
elevated SUA with the risk for development of prostate
cancer over a period of ten years following baseline
measurement [29]. Similarly, the increase in incident
prostate cancer observed in a Swedish cohort of MetS
males was associated with high SUA and insulin levels,
and both SUA and insulin were significant parallel pro-
spective markers of risk for prostate cancer. Indeed, a
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analysis to be an independent and significant (p < 0.04)
prospective risk factor for incident prostate cancer [21].
Further and much larger prospective studies conducted
on both male and female European cohorts confirmed
that high SUA (>6.71 mg/dl in men and >5.41 mg/dl in
women) measured at baseline was an independent risk
factor for death from all cancers compared to high nor-
mal SUA (4.6 mg/dl) [30,31]. These studies achieved
very high significance (adjusted HR, p < 0.0001) compar-
ing death ten years after measurement of antecedent
SUA, and as also noted by Levine [8], the strongest asso-
ciation between baseline SUA and cancer death was
achieved in the older patient quartile. These studies were
important as well because SUA obtained at baseline was
derived from apparently healthy people.
Important advances in statistical methods were subse-
quently employed to identify both the dose dependence
and time varying association of SUA and risk for all site
cancer mortality [32]. Finely stratified SUA obtained at
baseline and with 18.5 years of follow-up demonstrated
the impact of SUA on risk for cancer mortality at both
high and very low UA levels (J-Shaped dose–response
curve). This study was the first to identify SUA as both a
time dependent co-variant risk factor for overall cancer
incidence and one exhibiting a clear dose–response to
baseline SUA. Furthermore, amongst patients already
exhibiting terminal end stage cancer, weekly measure-
ment of SUA from the day of admission to cancer asso-
ciated death revealed that high SUA (>7.2 mg/dl)
significantly and independently predicted reduced sur-
vival time [26], revealing yet another dimension to the
risk for cancer mortality by elevated SUA.
Collectively, these data identify elevated SUA to be in-
dependently and significantly associated with the risk for
all site cancer incidence and mortality when measured
in advance of the development of cancer. While the inci-
dence of cancer and cancer mortality observed in hyper-
uricemia do not support the hypothesis that the
antioxidant properties of UA provide anti-cancer defense
in humans [4], the increment in cancer seen by Strasak
et al. [32] at low dose SUA may suggest a protective ef-
fect of SUA that is optimal near the normal human
levels of SUA. Furthermore, since low SUA may also re-
flect poor nutrition, these observations raise the possibil-
ity that a low SUA might have been a sentinel sign prior
to the recognition of cancer.
SUA, inflammation, and cancer
The association of elevated SUA with increased cancer
risk and mortality predicts that diseases associated with
hyperuricemia would also exhibit excess cancer risk and
mortality. Obesity, T2DM, insulin resistance, hyperten-
sion, MetS, and gout comprise a cluster of syndromesthat are associated with hyperuricemia, chronic inflam-
mation, and activated innate immunity [33,34] that may
be mediated in part by UA [35-38]. Elevated SUA has
been associated with prepubertal obese children present-
ing with insulin resistance [39], and it was identified as a
strong and reliable biomarker of MetS in obese young
women [40]. Meta-analyses have consistently shown that
SUA is a potent independent predictor of hypertension,
insulin resistance, and diabetes [41,42]. Furthermore,
confirmatory factor analysis of selected variables has
identified UA as a single common factor linking four of
the core components in the definition of MetS including
the HOMAR-IR measure of insulin resistance, mean ar-
terial pressure, the ratio of serum triglycerides to HDL-
cholesterol, and waist circumference [43]. Experimental
evidence is building that this factor could indeed repre-
sent UA, and recent analysis has identified its potential
phyiological role in T2DM and related disorders [44].
Excess cancer risk and incidence have been associated
with obesity, T2DM, insulin resistance, MetS, and gout
in large epidemiological analyses. For example, increased
all site cancer incidence has been observed in a large co-
hort of both male and female gout patients, and
increased overall cancer risk persisted in this population
throughout the 5 to 15 year follow-up from the time of
gout diagnosis [45]. The British Heart Disease and Dia-
betes Indicators Screened Cohort study (HDDRISC)
identified a cluster of biomarkers comprising numerous
inflammatory markers including SUA. SUA independ-
ently and as a component of the biomarker cluster was
predictive of all site cancer mortality in T2DM patients
through 21.5 years of follow-up [46]. This study also
confirmed the significant inverse relationship between
cancer mortality, SUA, and serum cholesterol in diabetic
patients. In a smaller but significant study of T2DM
patients from Northern Italy, high SUA was found to be
strongly associated with increased mortality that was al-
most entirely the result of all site neoplastic disease. Sta-
tistically significant increased cancer risk and mortality
was observed for SUA levels above 226 μM that per-
sisted through the highest SUA quartile [47]. These data
confirmed a massive study conducted earlier by the Can-
cer Prevention Study II of 1.2 million US men and
women that identified diabetes as an independent pre-
dictor of mortality from cancer of the colon, pancreas,
breast, liver, and bladder [48]. Although the CPS-II did
not compile data on SUA per se, a wide range of dietary
and lifestyle covariant parameters were included in the
analysis that have been found independenly to promote
hyperuricemia, including obesity, lack of exercise, west-
ern diet, red meat consumption, and alochol consump-
tion. Obesity, T2DM, insulin resistance, and MetS have
been specifically associated with increased risk of breast
cancer (BC) [22,36,49-52], BC recurrence [53,54], and
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tive Breast Cancer subtype that exhibits poor prognosis,
excess recurrence and metastasis, and worse chemother-
apeutic response was significantly more prevalent in
patients exhibiting MetS [36,57,58].
Chronic low grade inflammation is an underlying com-
ponent of obesity, T2DM, insulin resistance, and MetS
that is mediated in part by the pro-inflammatory proper-
ties of UA [35-38]. UA has been found to promote in-
flammation in two ways: as an MSU crystal or as a
soluble factor. Recent data have consolidated the idea
that the MSU crystal functions as a “danger signal”
recognized by Toll receptor-4 [9,10,59] and contributing
to many inflammatory disorders. Dead and dying cells
have been postulated as one source of UA in an inflam-
matory microenvironment, and activation of Toll recep-
tors by MSU crystals has been found to stimulate
leukocyte pro-inflammatory cytokine production [59,60].
On the other hand, in its soluble form, UA was found to
enter cells where it activated MAP kinases (p38 and
ERK), stimulated NFĸB, and induced expression of in-
flammatory mediators including MCP-1 and C-Reactive
Protein (CRP) [61-64]. These effects were likely
mediated by NADPH oxidase induced oxidative stress
inside the cell [61,62,65,66]. Importantly, additional
in vivo studies further demonstrated that lowering UA
pharmacologically improved inflammation both in la-
boratory animals and in patients with chronic kidney
disease [13,67]. Inflammatory processes induced by UA
in its soluble form require the function of transport
proteins (GLUT9, URAT1, and others) that translocate
soluble UA into cells activating wide genetic reprogram-
ming and is therefore mechanistically distinct from Toll
receptor activation by MSU crystals [68,69]. Adiponec-
tin, C-Reactive Protein, and Leptin are key components
of the chronic inflammatory environment that have been
associated with elevated SUA levels and cancer.Adiponectin, SUA, and cancer
Adiponectin is an anti-inflammatory protein whose
levels are reduced in obesity, T2DM, insulin resistance,
and MetS [70] and when reduced it has been associated
with increased risk of diverse cancers [71-73]. Reduced
circulating adiponectin was associated with the risk for
hypertension and renal injury, and it was inversely asso-
ciated with Leptin and CRP levels [74]. Low adiponectin
levels were found to be inversely associated with high
SUA in both young obese children and in adult women
presenting with MetS [70,75]. Therefore, it is highly sig-
nificant that in mouse models of MetS UA per se was
found to specifically reduce serum adiponectin level
[67], suggesting a functional link between SUA and adi-
ponectin expression.High circulating levels of adiponectin have been
strongly linked to improved BC risk and outcome
[23,36,76], and adiponectin treatment was found to at-
tenuate both cancer cell proliferation and mammary
tumor progression in xenograft analysis of aggressive BC
cells in mice [77]. The antitumor properties of adiponec-
tin may be in part related to its capacity to inhibit tumor
angiogenesis [78]. On the other hand, low circulating
adiponectin level has been a commonly observed risk
factor for BC [53,79-81]. Although most commonly
associated with post-meopausal BC [23,76,80], low
serum adiponectin was associated with increased BC risk
in both pre- and post-menopausal Japanese patients
[81]. Low circulating adiponectin was associated with
increased BC risk overall [53,79-81], BC recurrence and
metastasis [53,82], and increased BC mortality [79]. In
transgenic mouse models of mammary tumorigenesis
that utilized the MMTV driven polyoma middle-T anti-
gen, haploinsufficiency of adiponectin was found to ac-
celerate mammary tumor onset and increase
aggressiveness and tumor development [83]. Further-
more, increased lung metastases were observed by a dif-
ferent group of investigators using the same model of
mammary tumorigenesis [84]. This group made the ap-
parently contradictory observation that haploinsuffi-
ciency of adiponectin produced a delayed angiogenic
response, an observation that was explained as a poten-
tial angio-mimetic property of adiponectin acting in the
early, but not late, stages of tumor vascularization [85].
Current data indicate that adiponetin may in part exert
its effects on mammary tumor cells by inhibition of Wnt
signalling, Akt activity, and the tumor suppressor LKB1
[77,82]. Furthermore, loss of adiponectin has been found
to promote hyperactivation of PI3K/Akt phosphorylation
and signalling that was associated with increased prolif-
eration of mammary tumor cells [83]. Together,
these data are consistent with a role for high SUA in
depressing circulating adiponectin level that is in turn
associated with increased tumorigenesis, tumor size,
and metastasis.
C-reactive protein, SUA, and cancer
Elevated SUA has been specifically associated with high
circulating levels of the pro-inflammatory mediator C-
Reactive Protein (CRP) as well as the pro-inflammatory
mediators IL-6 and TNFα in a large cross-sectional
European cohort [86]. Co-expression of high CRP and
elevated SUA was identified in patients with T2DM [87]
or MetS [88-90] where it was specifically associated with
CVD or insulin resistance. Elevated levels of CRP were
positively associated with increased BC risk and risk of
cancer death [36,91], and they were positively correlated
with SUA levels in early and advanced stages of BC [92].
High circulating levels of CRP were also associated with
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and renal cell cancers [96]. Significantly, pharmacololo-
gical inhibition of XOR with allopurinol concomittantly
reduced both SUA and CRP in patients with either nor-
mal renal function or in patients expressing chronic kid-
ney disease [13,97,98], and direct support for a
functional role of UA in the production of CRP was
obtained in vascular smooth muscle cells and endothelial
cells where UA stimulated secretion of CRP as well as
MCP-1 [61,62].
Despite these strong associations between CRP, SUA,
and the risk for diverse types of cancer, CRP is unlikely
to be a specifc cause of cancer. Analysis of the four most
common single nucleotide polymorphisms (SNPs) found
in the CRP gene that were associated with increased cir-
culating CRP (95% CI of 58-87% increase) revealed that
there was no increase in cancer risk or incidence asso-
ciated with these SNPs [99]. This study employed a large
European cohort of 10,215 subjects and demonstrated
an insignificant odds ratio for cancer associated with
doubling of CRP level of 0.94 (95% CI of 0.81 to 1.08).
While these data indicated that elevated CRP per se was
unlikely to be a cause of cancer, they did identify CRP as
an important prognostic biomarker of outcome that
revealed an underlying inflammatory process associated
with high SUA levels [100].
Leptin, SUA, and cancer
Leptin has been described as the missing link between
hyperuricemia and obesity, MetS, T2DM, and related
disorders [101,102]. Leptin is the product of the Obese
gene (ob), and loss of function mutations in mouse and
human ob genes results in profound obesity and T2DM
[103,104]. Deficiency in receptors for leptin (LepRdb-db
and Leprdb-lb) in mice likewise result in obesity, diabetes,
pre-diabetes, and MetS [67,105]. Thus, it has been pos-
tulated that while leptin and leptin receptor signaling act
to suppress food intake and maintain long-term energy
balance, the excess serum leptin found in obesity may
reflect a state of leptin resistance [104].
Leptin, CRP, and SUA are directly correlated in
patients presenting with MetS [40,74,106-108], and in-
versely correlated with adiponectin level [75,107]. Leptin
has been postulated to be a key mediator linking obesity
and hyperuricemia as a potential regulator of SUA level.
Statistical models have revealed strong positive associ-
ation between circulating leptin and SUA, and in multi-
factorial regression analyses serum leptin could explain
34-42% of the variance in SUA in both men and women
in a hypertensive cohort of Turkish patients [101]. Lep-
tin and SUA were strongly associated in healthy and
T2DM subjects [102], in patients presenting with MetsS,
central obesity, and insulin resistance [109,110], and in-
deed in a Japanese cohort of patients with gout, goutwas associated with excess MetS compared to normal
controls and was strongly associated with elevated leptin
and SUA [111].
There is some evidence that the rise in uric acid may
be the consequence of elevated leptin levels because loss
of leptin receptor signaling also engenders hyperurice-
mia [67]. Fruehwald-Schultes et al. [102] have suggested
a mechanism that may in part explain this observation.
They have postulated that leptin may directly impair UA
excretion in the kidney and that in obesity elevated lep-
tin levels may impair renal clearance of UA resulting in
hyperuricemia. Hyperuricemic, leptin receptor deficient
mice also show excessive hepatic XOR expression sug-
gesting that leptin receptor signaling may also down
regulate hepatic XOR expression [67]. Thus, leptin may
affect SUA at both the level of production and renal
clearance. Taken together, these results suggest an add-
itional link between SUA and cancer: with leptin regulat-
ing SUA levels in subjects with obesity, MetS, and
T2DM.
There is also experimental evidence that UA may
have a role in mediating leptin resistance. Recent stud-
ies have reported that elevated SUA precedes the devel-
opment of MetS in humans [42], suggesting that it
might precede the development of leptin resistance.
Experimental studies found that lowering SUA pharma-
cologically improved features of MetS in rats in
response to fructose feeding, including the development
of insulin resistance, hypertriglyceridemia, and elevated
blood pressure [19]. More recently, a pilot study found
that lowering SUA in fructose-fed rats also reduced
leptin expression in visceral fat tissues [112]. Further
studies will be required to determine if the reduced lep-
tin expression would also translate into reduced leptin
resistance.
The pro-tumorigenic role of leptin on breast, colon,
prostate, and ovarian cancer in patients with obesity,
MetS, and T2DM was recently reviewed [85,113,114].
Briefly, mounting evidence suggests that the leptin to
adiponectin ratio is sensitive to states of obesity, T2DM,
and MetS and that the ratio is a key clinical determinant
of cancer tumorigenesis and/or carcinogenesis with ele-
vated leptin being associated with greater cancer risk
and poor outcome. The pro-tumorigenic effect of leptin
appears to be mediated in part by its stimulation of can-
cer cell proliferation via ERK, JNK, and STAT3 path-
ways. While leptin is an apparent growth factor for BC
that is elevated in BC patients [36,115], its mechanism
of tumor promotion remains equivocal [36]. Import-
antly, leptin receptors are expressed on many cancer
cells including those of the breast [116], and exposure of
MCF-7 BC cells to leptin induced cell proliferation that
was mediated in part by activation of MAPK [117]. As
described below, we speculate that leptin may further
Fini et al. Clinical and Translational Medicine 2012, 1:16 Page 6 of 15
http://www.clintransmed.com/content/1/1/16stimulate proliferation and tumorigenesis by down-
regulating cancer cell XOR.
UA transport and cancer
Homeostasis of SUA in humans is maintained by the bi-
directional flux of SUA in renal proximal tubule epithe-
lial cells. Presently, no less than 10 plasma membrane
transport proteins have been found to contribute to UA
movement into and out of the renal proximal tubule epi-
thelial cells [68]. Roles for the Organic Anion Transport
(OAT) proteins OAT-1, -3, -4, 10, ABCG2, NPT1/4,
MRP4, URAT1, and GLUT9 in renal UA homeostasis
and extra-renal distribution are only partially under-
stood. For many of these, a large array of accessory
proteins has been identified that are required for co-
transport function [68]. The two major renal transporter
proteins identified to date are the high affinity trans-
porter URAT1 (SLC22A12) that mediates uptake of
urate from the urine into the renal proximal tubular cell,
and GLUT9 (SLC2A9/URATv1) which is a voltage-
sensitive uniporter that mediates the export of UA from
the proximal tubular cell into the circulation [118,119].
The association of URAT1 or GLUT9 with cancer
remains largely untested at the present time.
The ABCG2 locus encoding a member of the ATP-
binding cassette transporter proteins, also known as the
Breast Cancer Resistance Protein (BCRP), has been in-
tensively studied for its role in resistance to cancer
chemotherapy. ABCG2 is an important efflux trans-
porter of xenobiotic compounds, including many anti-
neoplastic drugs, and its inhibition or mutation can
improve cancer chemotherapy [120]. Genome wide asso-
ciation studies (GWAS) for hyperuricemia identified
ABCG2 as tightly associated with hyperuricemia and
gout [121-124]. Functional analysis confirmed the princi-
pal role of ABCG2 in normal physiology, independent of
drug efflux, as that of UA efflux. These studies identified
several SNP associated with the ABCG2 locus that were
functionally involved in UA efflux. In particular, SNP
rs2231142 generated the C421A DNA mutation causing
the Q141K amino acid substitution. Q141K both
reduced ABCG2 expression and blocked UA efflux, and
it is a common polymorphism causing gout and hyper-
uricemia in Caucasian, Black, Japanese, and Chinese
populations [121-124].
Prospective analysis of the C421A polymorphism in
untreated patient populations, those not undergoing any
chemotherapeutic drug treatment, demonstrated signifi-
cant and markedly increased risk for developing nonpa-
pillary renal cell carcinoma [125], an increased risk and
poor survival prognosis for patients with diffuse large B-
cell lymphoma [126], and increased risk and poor
survival prognosis for patients with acute leukemia
[127]. These data strongly support the premise thathyperuricemia can be an important risk factor for cancer
incidence and mortality, and they underscore the im-
portance of conducting more expansive analysis of other
UA transport proteins in diverse cancer settings.
Together these data suggest a model by which both
extracellular UA and intracellular UA may collaborate
in transformation toward a highly aggressive cancer
(Figure 1). Inflammatory stress induced by elevated intra-
cellular UA may promote transformation, while elevated
extracellular UA may further stimulate tumor cell pro-
liferation, migration, and survival contributing to the
development of highly aggressive cancer.
Tumor cell XOR, UA, and cancer
Although the increased cancer burden associated with
hyperuricemia in obesity, T2DM, and MetS has sug-
gested the relevance of modulating XOR activity in can-
cer therapy, presently available strategies may be
inappropriate for many types of cancer. Allopurinol and
febuxostat are FDA approved systemic pharmacological
inhibitors that block XOR activity in all cells of the body
[2,128]. However, inhibition of XOR in tumor cells per
se is a potentially confounding factor that limits current
strategies for the pharmacological control of SUA in
cancer management.
Decreased or absent tumor cell XOR has been
observed in the most aggressive human breast cancer
[129], gastric cancer [130], colorectal cancer [131], ovar-
ian cancer [132], non-small-cell lung cancer [133], and
in rat hepatic cancer [134,135]. For breast, gastric, colo-
rectal, ovarian, and lung cancers in humans the
decreased XOR activity was associated with worse clin-
ical prognosis and unfavorable outcome (reduced sur-
vival). Poor XOR expression was also associated with
poorly differentiated breast, gastric, and colorectal can-
cers and was associated with over two fold increased risk
of distant metastasis. While it has been suggested that
the decreased purine catabolism and increased activity
of salvage pathway enzymes would favor tumor cell
growth [134,135], the decreased XOR activity observed
in highly aggressive cancer cells appears to exert unex-
pected effects on cancer cell differentiation that also
favors tumorigenesis and metastasis.
High levels of XOR were found to repress and low
levels of XOR to stimulate BC cell aggressiveness
in vitro as measured by increases in COX-2, MMP-1 se-
cretion, and in vitro migration rate [136], and this
appears to reflect the unexpected role played by XOR in
BC cell differentiation. XOR activity was found to modu-
late expression of the inhibitor of differentiation protein,
Id1. High levels of Id1 have been linked to highly aggres-
sive and metaplastic BC, and the inhibition of Id1 by
epithelial XOR was postulated to reduce BC aggressive-
ness and/or metastasis. Furthermore, loss of XOR
Figure 1 Hyperuricemia contributes to tumorigenesis by promoting both transformation and tumor cell proliferation, migration,
and survival. High levels of extracellular UA present in the serum or in the local microenvironment of tumor cells exerts many pro-inflammatory
effects that contribute to tumorigenesis. While extracellular UA has antioxidant effects that may protect normal cells from transformation, entry of
UA into cells can generate inflammatory stress that arises from the effects of intracellular UA on ROS/RNS generation and COX-2 activation.
Stimulation of cancer cells by UA further promotes proliferation, migration, and survival that mediates progression from early stage cancer to
highly aggressive cancer.
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Id1 level and increased BC cell aggressiveness [137]. Re-
markably, epithelial XOR has now been found to modu-
late three of the critical signature genes mediating BC
aggressiveness and metastasis: COX-2, MMP-1, and Id1
[136,137] consistent with the observed increase in clin-
ical recurrence and metastasis in poor XOR expressing
cancers. These data indicate that systemic pharmaco-
logical inhibition of XOR with the goal of reducing SUA
might exacerbate tumorigenesis or metastasis by inhib-
ition of tumor cell XOR.
Little is known about the response of cancer cells
themselves to UA. UA present in the tumor microenvir-
onment may contribute to tumorigenesis or metastasis
in ways that are distinct from the pro-inflammatory pro-
cesses elicited by SUA. Exposure of human mammary
cancer cells or mouse mammary epithelial cells in vitro
to a wide concentration range of UA dose dependently
increased migratory rate of both cells [136]. Migratory
rate of both cells was significantly increased at even low
normal levels of UA. Thus, treatment of BC cells with
exogenous UA in vitro appeared to replicate the state of
cells from more aggressive tumors with increased metas-
tasis that have been associated with aggressive breast
and colorectal cancer in patients with MetS
[23,138,139]. It was postulated that the high levels of
SUA observed in obesity, T2DM, and MetS may repress
tumor cell XOR and inhibit its function in promotingepithelial cancer cell differentiation [136], and it has
been shown that physiological levels of UA can indeed
repress XOR activity [140]. However, it can be imagined
as well that highly aggressive tumor cells that are natur-
ally deficient in XOR expression [134-136] may be both
poorly set up to promote differentiation but still capable
of responding to exogenous UA by increased aggressive-
ness. Furthermore, we postulate that the elevated levels
of leptin found in obesity, T2DM, and MetS may collab-
orate with UA and contribute to tumorigenesis and me-
tastasis by down regulation of tumor cell XOR. Taken
together these data suggest a mechanism by which
diminished tumor cell XOR in conjunction with hyper-
uricemia and elevated leptin promote cancer cell prolif-
eration, migration, and survival (Figure 2).The special cases of leukemia and tumor lysis syndrome
Certain leukemias and the Tumor Lysis Syndrome are
cancer states that are also associated with severe hyper-
uricemia. In these cases, the hyperuricemia arises as a
result of cell lysis, release of purines, and subsequent UA
accumulation. XOR plays a prominent role in both can-
cer types as the source of UA, and current therapies are
directed at inhibition of XOR with allopurinol or
Febuxostat and degradation of the SUA using recombin-
ant uricase (Rasburicase). Recent reviews provide excel-
lent discussion of both cancer states and therapeutic
Figure 2 Elevated UA and reduced intracellular XOR contribute to tumor cell proliferation, migration, and survival. ROS scavenging
properties of extracellular UA are postulated to promote cancer cell growth and survival in part by protecting cells from oxidative stress induced
apoptosis. This arises because tumor cells in general exhibit poor capacity to survive oxidative stress compared with normal cells and may
therefore be protected by the antioxidant ROS scavenging properties of UA (J-Shaped dose–response curve; [32]). Loss of XOR expression in the
most aggressive cancer cells also contributes to tumor cell proliferation, migration, and survival. In cells showing high level XOR expression, XOR
modulates COX-2 and MMP expression reducing migratory activity [136]. However, loss of XOR expression in cancer cells increases COX-2 levels,
MMP expression, and migratory activity. Loss of XOR expression may arise for many reasons, including the entry of UA into cancer cells. Import of
UA into XOR deficient cancer cells may further promote proliferation and survival in part by stimulating expression of COX-2. The diminished XOR
expression found in aggressive cancer cells would result in shunting the XOR substrates hypoxanthine and xanthine into the salvage pathway,
providing substrates for nucleotide synthesis, tumor growth, and proliferation. The independent effects of leptin on cancer cells notwithstanding
[85,113], the elevated levels of leptin observed in MetS associated cancer may also drive these processes both by inducing hyperuricemia and by
down regulating cancer cell XOR.
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[141,142].UA as a signaling molecule
Low physiological levels of UA stimulated mammary
cancer cell aggressiveness in vitro, and in cells expres-
sing UA transport proteins capable of importing UA,
UA derived from the serum, tumor associated adipo-
cytes, macrophages, or other cells may also stimulate
tumorigenesis and/or metastasis. At the present time,
very little is known about the mechanisms by which UA
may signal to cancer cells. However, some key observa-
tions have been generated from non-cancerous cells that
may provide a useful background for further studies
conducted on cancer cells themselves.Renal epithelial cells
Uptake of UA by primary renal proximal tubule epithe-
lial cells (PTEC) of the rabbit inhibited in vitro cell pro-
liferation that was mediated by at least two signaling
mechanisms [143]. Cell proliferation was inhibited over
a broad concentration range of UA, achieved signifi-
cance at 100 μM, and was profound at the hyperurice-
mic level of 500 μM. Co-treatment of PTEC with
pharmacological inhibitors demonstrated that the inhib-
ition of PTEC proliferation by UA was mediated by the
transient activation of MAP Kinases p38, JNK, and
ERK1/2. This effect was apparently transduced by UA
activation of protein kinase C, cytoplasmic phospholip-
ase A2, and NF-κB that was interpreted to comprise di-
vergent pathways. A more complete picture of the
response of PTEC to UA was obtained using a
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[69]. Stable heavy isotope labeling of HK-2 cells was
achieved using [13 C6]-Lys (heavy) labeling combined
with exposure to 500 μM UA. Cells were mixed with
control cells (no UA and Lys light), proteins prepared,
trypsin digested, fractionated by liquid chromatography-
mass spectrometry (LC-MS), and quantified by the rela-
tive ratio of isotopic peptide pairs. After correction for
false discovery rate 782 proteins (of 13,652 peptides)
were found altered by exposure to UA. Pathway network
and functional group analysis identified 42 proteins asso-
ciated with cell proliferation and 49 with apoptosis pla-
cing MAPK and NF-κB signaling networks at the center
of UA signaling in PTEC. While details of this analysis
remain to be fully deciphered, they establish the primacy
of proliferation and apoptosis pathways regulated by UA
in renal PTEC.
Vascular Smooth Muscle Cells
Perhaps the earliest observation that UA signaling may
be involved in cell proliferation was generated by the ob-
servation that primary rat aortic vascular smooth muscle
cell (VSMC) proliferation was stimulated by UA over a
concentration range of 50 to 300 μM, an effect trans-
duced in part by UA activation of cMyc and PDGF A-
chain [144]. Unlike the human VSMC, rat VSMC do not
express the URAT1 transporter or members of the OAT
family, and a voltage sensitive transporter (possibly
GLUT9 or URAT) may instead mediate UA induced
proliferation [145]. Careful preparation of crystal free
UA enabled the identification of signaling pathways
induced by UA in rat VSMC [61]. NF-κB, AP-1, and the
MAP kinases p38 and ERK-1/2 were activated by UA at
levels from 100 to 700 μM. In addition to its effects on
VSMC proliferation, UA was also found to activate the
pro-inflammatory mediators MCP-1 and COX-2 [145].
Adipocytes
In differentiated mouse 3 T3-L1 derived adipocytes, but
not undifferentiated 3 T3-L1 cells, UA was found to in-
duce phospho-activation of p38 and ERK-1/2 MAP
Kinases by a pathway involving activation of the
NADPH oxidase and ROS generation [63]. Induction
proceeded over a UA concentration range of 100 –
700 μM and was blocked by URAT1 inhibition with pro-
benecid. While UA induced an apparent oxidative and
nitrosative stress, it was also found subsequently to acti-
vate the inflammatory state of these cells [67]. UA at
both normo- and hyperuricemic levels simultaneously
increased steady state mRNA expression of the leukocyte
chemokine MCP-1 and decreased expression of the anti-
inflammatory protein adiponectin, and these data were
largely replicated in an in vivo mouse model. Induction
of MCP-1 was sensitive to both superoxide scavengingand apocynin inhibition as well as the PPARγ agonist
rosiglitazone suggesting the involvement of the NADPH
oxidase/ROS system and PPARγ, while inhibition of adi-
ponectin appeared to involve PPARγ alone. These obser-
vations are consistent with the observed role of
intracellular XOR in promoting 3 T3-L1 differentiation
and adipogenesis in vivo in mice, an effect that was
mediated in part by regulation of PPARγ activity [146].
While XOR dependent redox mechanisms were impli-
cated in adipogenesis, the potential impact of UA per se
on adipocyte differentiation has not been determined.
Leukocytes
While leukocytes exhibit a well-characterized inflamma-
tory response to MSU crystals [10,59], exposure of
RAW264.7 mouse macrophages and differentiated
human U937 cells to pH adjusted and crystal free UA
revealed a dramatic effect on macrophage inflammatory
polarization [147]. UA from 30 to 1000 μM dose de-
pendently modulated levels of the macrophage M2
polarization markers Arginase-1, CD36, and CD206, and
this effect was transduced in part by inhibition of PPARγ
sumoylation, an effect that promoted the inflammatory
M1 state. Although the identity of the UA transporter
mediating the response to UA was not identified,
GLUT9 is expressed on leukocytes and remains a rea-
sonable candidate for this function [148]. As an en-
dogenous product of leukocytes, XOR activity exerts
many effects on inflammatory potential, cytokine synthe-
sis, and lipid uptake [147,149,150]. Because treatment of
mouse macrophages with oxonic acid, an inhibitor of
uricase, replicated many of the effects of exogenous UA,
it was postulated that intracellular UA was in part re-
sponsible for the effects of endogenous XOR generated
UA on leukocyte function.
UA as an Intracellular Redox Signal
While the detailed mechanism by which UA contributes
to intracellular signaling networks is unknown, it has
been postulated to involve intracellular redox dependent
mechanisms. For example, in 3 T3-L1 derived adipocytes
UA uptake was associated with intracellular ROS accu-
mulation, and inhibition with apocynin implicated the
NADPH oxidase as a source of ROS and placed ROS
generation upstream of NF-κB, p38, and ERK-1/2 MAP
Kinase activation [63,67]. These observations dovetail
well with data generated in renal epithelial cells that
identified several redox sensitive components of the up-
stream network mediating MAPK activation that are
induced by UA [69]. For example, RAC1, MAPK1,
MAP2K, MAP4K were all induced by UA and are
known to exhibit redox-sensitive activation that in turn
promotes phospho-activation of p38 and ERK-1/2
MAPK [151]. Although not well understood, induction
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cells (PANC-1) following radiation exposure or treat-
ment with 5-fluorocracil was found to mediate the in-
duction of MHC class-I related proteins MICA/B that in
turn promoted sensitivity to NK-92 cell killing [152].
While the signaling mechanism responsible for the in-
ductive effect of UA on MICA/B expression were not
identified, marked elevation in MICA/B protein levels
were clearly evident that were inhibited by treatment
with allopurinol in vitro.
Conclusions
Two risk factors for the development and progression of
breast cancers that are amenable to life style modifica-
tion are chronic inflammation and the metabolic syn-
drome. To ameliorate inflammation, clinical trials
abound that focus on COX-2 inhibition. The principal
factors felt to mediate cancer risk from metabolic syn-
drome have included insulin resistance, high IGF1R sig-
naling and higher tissue levels of estrogen (for breast
cancer). This review proposes two new targets that may
mechanistically integrate inflammation and metabolic
syndrome, have been largely ignored, and are known to
be druggable. Realization of the important role played by
UA as a signaling molecule mediating the inflammatoryFigure 3 Hypothesis for the protumorigenic role of UA in the breast
associated and/or distant adipocytes through a UA-specific transporter (like
ROS. As observed in other inflammatory environments, UA at both normo-
mRNA expression of the leukocyte chemokine MCP-1 and decrease expres
entering adipocytes may down-regulate expression of XOR which is known
adipogenesis and adiponectin expression. Furthermore, as previously show
Arginase-1, CD36, and CD206, an effect transduced in part by inhibition of
activation. Presently, the identity of the UA transporter mediating macroph
product of leukocytes, XOR activity may exert many effects on inflammator
findings support the hypothesis that hyperuricemia might be partially resp
microenvironment that contributes to tumor cell proliferation and metastaeffects of hyperuricemia in adipocytes and leukocytes,
as well as in signaling to cancer cells (Figure 3) has
emphasized the relevance of managing UA therapeutic-
ally which could significantly improve treatment strat-
egies for cancer that is associated with hyperuricemic
disorders.
Significant side effects of systemic chronic inhibition
of XOR have been recognized for many years. Con-
founding problems associated with chronic inhibition of
XOR include diarrhea, diminished renal function,
leukopenia, hypersensitivity reactions, vasculitis [3], and
even exacerbation of vascular injury through recently
identified effects on nitrite reduction [153]. While the
frequency of allopurinol hypersensitivity syndrome may
be significantly reduced by avoiding the administration
of allopurinol to subjects bearing the HLA-B58 haplo-
type [154], it remains a serious syndrome with high mor-
tality. Systemic pharmacological inhibition of cancer cell
XOR could theoretically exacerbate tumorigenesis, me-
tastasis, and mortality. These unwanted side effects
underscore the urgent need for mechanism based pre-
clinical studies that can identify optimal strategies for
management of hyperuricemia in relevant cancer mod-
els. Recently developed conditional knockout models for
XOR that are based on CRE/Lox technology may be ofcancer microenvironment. UA is postulated to enter tumor
ly URAT1) where it activates the NADPH Oxidase (NOX), generating
and hyperuricemic levels may simultaneously increase steady state
sion of the anti-inflammatory protein adiponectin. In addition, UA
as a crucial upstream regulator of PPAR-γ, a master regulator of
n, UA may reduce levels of the macrophage antiinflammatory markers
PPARγ sumoylation that in turn promotes macrophage inflammatory
age response to UA has not been identified. As an endogenous
y potential, cytokine synthesis, and lipid uptake. Together, these
onsible for the low grade inflammation present in the breast tumor
sis.
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target cells, such as hepatocytes or adipocytes, that are
principal sources of SUA [137]. Likewise, similar CRE/
Lox technology applied to the GLUT9 transporter [155]
will be highly valuable in delineating the role of SUA in
pre-clinical models of human cancer as well. The goal of
specifically managing SUA without exacerbating tumori-
genesis and/or metastasis will undoubtedly involve novel
therapeutic strategies, but these efforts could signifi-
cantly improve therapeutic strategy for cancer associated
with obesity, T2DM, and MetS.
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